An Overview of Recent Patents on Biogenic Nanopharmaceutical Products

Biogenic nanopharmaceuticals, synthesized through biological methods using plants, microorganisms, and biomolecules, have emerged as a promising alternative to conventional drug delivery systems. These nanoparticles offer unique advantages, including enhanced biocompatibility, improved pharmacokinetics, and environmentally friendly production processes. Their applications span targeted drug delivery, sustained release mechanisms, and advanced therapeutic approaches, such as cancer treatment and antimicrobial therapies. The field has seen rapid growth, with significant innovations reflected in recent patents emphasizing green synthesis, hybrid delivery technologies, and novel therapeutic uses. Despite these advances, the industry faces critical challenges, including scalability, regulatory hurdles, and intellectual property conflicts. Variability in biological materials and concerns over reproducibility pose additional complexities in clinical translation. Ethical and environmental considerations, particularly regarding the sustainable sourcing of biogenic materials, further highlight the need for responsible innovation. Future progress in this domain relies on addressing these obstacles through collaborative research, strategic patenting, and interdisciplinary approaches. By integrating biogenic nanotechnology into global healthcare systems, these innovations could redefine treatment paradigms, offering safer, more effective, and sustainable therapeutic solutions. This chapter explores the recent advances, challenges, and future directions of biogenic nanopharmaceuticals, underscoring their potential to revolutionize modern medicine and healthcare.